“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
The India business continues to be the second largest business unit for Lupin, contributing 34% to the topline and signiﬁcantly to the bottomline. Lupin’s branded generics sales grew by 13.6% in FY20. Lupin’s branded generic business is currently placed at 6th position in the Indian Pharmaceutical Market (IPM). The branded generics business has consistently outpaced the IPM with a four-year CAGR of 11.7% vs. IPM CAGR of 9.4%. Importantly, over the last four years, we have improved our market share from 3.46% in FY16 to 3.61% in FY20. Overall, Lupin retains the 4th position in the high growth chronic segment. The chronic segment has improved in salience to 62% of total revenues and the acute segment contributes the balance 38%.
Our top ﬁve therapies, cardiology, anti-diabetes, respiratory, anti-infective and gastrointestinal contribute more than 74% of total sales. We continue to lead in the anti-TB segment and maintain 2nd position in the respiratory and 3rd position in the anti-diabetes and cardiology segments. We have grown signiﬁcantly in the anti-diabetes segment with growth of 18.4% versus IPM's growth of 11.8%, resulting in improved market share from 7.9% in FY19 to 8.4% in FY20. We now have 10 Lupin brands that feature in the Top 300 brands of the IPM. In FY20, Lupin successfully launched three new divisions focused on the urology, dermatology and pediatric respiratory therapy areas.
We also launched 'Adhero,' a ﬁrst of its kind Bluetooth-Enabled Smart Device in India to support treatment of respiratory disease. We continue to demonstrate leadership in launching new products and rank 3rd in the IPM in the 12 months New Product Introduction Index. We are focused on building therapy-speciﬁc scientiﬁc platforms to enable long-term and meaningful association with focused specialties. In FY20, Lupin associated with the American College of Gastroenterology (ACG) to create a platform for gastroenterologists and similarly with Mayo Clinic for Orthopedics. Lupin has been at the forefront of digital transformation and technology adoption. 'Anya,' Lupin’s Health Chatbot launched in FY20, can answer queries on respiratory ailments, Hypertension and Diabetes. It can even respond in Hindi and Tamil for the latter two conditions. Through our social media channels, we continue to engage with health care professionals through live webinars and content focused on therapeutic advancement. Lupin has also partnered with new-age startups to leverage their digital prowess and reach patients for educating them on developing healthy habits and improving adherence.
Our OTC division, LupinLife Consumer Health, is committed to bringing value-based oﬀerings to consumers by introducing well positioned brands based on robust scientiﬁc evidence. In FY20, LupinLife reinforced its market presence by strengthening its portfolio and distribution reach. We continue on the growth trajectory with double-digit growth in sales despite headwinds in some markets. There were several Rx to OTC brand shifts in FY20, especially Lupizyme (used for the treatment of digestion related problems) and Aptivate (an appetite stimulant) that have bolstered the product portfolio. Along with introducing brand extensions such as Softovac®O (Orange ﬂavor), we also initiated multiple advertising campaigns for our key brands.
COMPLETE LIST OF PRODUCTS
The Company's concerted focus on the semi-acute therapy is the crux of the Lupin division, which has enabled the Company to attain market leadership in the Anti-TB segment of IPM. It continues to lead the pack in the anti-TB segment, as well as maintain its presence in the cardiovascular, diabetic, asthma and CNS space. The Lupin division now commands 46% market share in a INR 2,920 million anti-TB market and grew by 7% during the year.
Key Products : Lupin Pharma
The Respiratory Cluster comprising of 3 divisions Respira, Respira Specialty Care & Spiritus is responsible for the Company’s business in the Inhalation space, targeting core therapy segments such as Asthma, Chronic Obstructive Respiratory Disease ( COPD), Allergic Rhinitis and Interstitial Lung Diseases (ILD’s). Respiratory Cluster continues to garner market share and has emerged as the 2nd largest player in the Inhalation space with a market share of 16.2 %( IMS MAT Apr 2020 ). While relentlessly pursuing improvement in three areas important to respiratory therapy, viz. awareness, diagnosis & adherence, the team also facilitates world class academic initiatives in the field of respiratory medicine.
Lupin has entered into an alliance with Omron Healthcare India, a leading healthcare monitoring brand, to strengthen respiratory disease management facilities in India mainly focusing on Asthma and COPD patients. Aimed at improving lives and contributing to a better society through use of innovative technology, the alliance aims to support the whole journey of a respiratory patient right from diagnosis to treatment by giving patients an ideal one-stop ecosystem providing screening, diagnostics, drug delivery, device, aided with advanced technology and digital tools all under one roof.
Key Products : LUPIN RESPIRA
This division focuses on Anti-Infective, Gastroenterology and Osteoarthritis businesses as well as acute therapy areas like Anti-Biotics and Pain Management. It covers almost 16 specialties and engages with everybody ranging from a general practitioner to a gastroenterologist. In keeping with its tradition, Endeavour continues to consistently outperform the market where it was ranked the 2nd largest player in its participated market, clocking in a growth of 14% during FY 2014 (AIOCD AWACS MAT Feb, 2014).
Key Products : ENDEAVOUR
Lupin’s Critical Care division focuses mainly on four therapy areas; Critical Care, Orthopaedic, Urology & GP/CP/Surgery based products. As per SMSRC Prescription data, Maxter clocked in growth of 19% while the market growth was just 4% during the same period (SMSRC Mar-Feb 2014 over Mar-Feb 2013).
Key Products : MAXTER
Lupin India formulation business’s flagship division continued to outperform the market with the division emerging as the 3rd largest player within the Indian cardiology market.
The Company continues to expand on its association with the American College of Cardiology (ACC) where we conducted a special program called Rhythm 2013, an Advanced ECG Program in seven locations across India with over 1,500 doctors with international certification participating in the proceedings.
Pinnacle also conducted an Emergency Cardiovascular Care workshop in association with and certification from the American Heart association (AHA) for doctors across different cities in India. The division also conducted and facilitated Innovative Doctor Engagement webcasts in the area of Hypertension and Dyslipidemia.
Key Products : Pinnacle CVS
Set up in FY 2010, Lupin CVN is focused on the Nephrology and Urology segments. The Lupin CVN division has grown at a CAGR of 28% over the last 5 years. The division continues to build on its leadership credentials in its participated markets where it is ranked 1st by prescription.
The division continues to innovate by creating specialized webinars and was the first to introduce QR Code Interactive Communications to communicate with doctors and patients.
India is unfortunately often referred to as the future diabetic capital of the world. It is estimated that by 2030, every fifth diabetic will be an Indian. Since inception, the Lupin Diabetes Care division has been scripting new chapters in its fight against diabetes. Lupin Diabetes Care has consistently outperformed the market and ranked as the 3rd largest player in its participated market with a growth of 28% during FY 2014 (AIOCD AWACS MAT Feb 2014).
The division has created very strong patient care programs like Arogya and The Wellness program. The Arogya diabetes program is a first-of-its kind initiative to screen 37,000 patients with over 2,000 doctors participating across India. It has not only enabled diabetes and hypertension screening and diagnosis but also covers lipid and renal profile and thyroid screening for patients. The Tereos Wellness Program (TWP) is an exclusive unique patient support venture where qualified nurses and periodic laboratory testing at the patients door step is ensuring better monitoring of the patient.
Key Products : Lupin Diabetes Care
Lupin is ranked 8th in the CNS segment, having grown by 7% in FY 2014 (AIOCD AWACS MAT Feb 2014). Mindvision division successfully launched new products in major sub-segments such as Anti-Depressants, Anti-Epileptics, Pain and Stroke. Mindvision enjoys strong brand equity in the Neurology and Psychiatry segment.
Key Products : MINDVISION
The Lupin Femina division was launched in FY 2009 to spearhead the Company's entry into the women's health care segment. Lupin Femina registered a dynamic growth of 134% and launched seven new brands during FY 2010. Lupin Femina also launched two in-licensed products in the Gynaecology segment during the year, namely Faa-20 and Luprolide.
This specialized ophthalmic division of the Company is ranked amongst the top 10 in its represented market within the IPM. The division grew by 48% in FY 2014 as against a market which grew by just 7% (AIOCD AWACS MAT Feb 2014).
Lupin Blue Eyes in association with Eye Bank Association of India (EBAI) launched the ‘Punarjyoti’ campaign to promote eye donation in the country after death.
Key Products : Lupin Blue Eyes
Formed in FY 2013, Lupin Ikonic is the youngest division within the Company and the 2nd specialized division to be focusing on Neuropsychiatry and Oncology catering to neurologists, psychiatrists and oncologists.
Key Products : Lupin Ikonic
Division Phoenix is launched at the start of this FY’16-17 to have focused approach for Gynecologists (Gyn) and Dermatologists (Derma). Phoenix has established brands and reputation in gynecology segment with brands such as Corcium, Faa, Lupigest and Yamini though we are relatively new player in Dermatology segment and doesn’t have a significant presence in it. This division is launched with an objective to capitalize on the opportunity lying in these segments (Gyn & Derma) as the IRM is growing with healthy double digit growth rate. Our product range is catering to following segments in both therapy areas:
Gynecology Segment: Nutrition during obstetrics and beyond, Anemia, Contraception, Progesterone, Gonadotropins, Infertility, Intimate Hygiene
Dermatology Segment: Triple drug combination (Steroid + Anti. Fungal + Anti. Infective) for Mixed Skin infections, Sunscreen, Melasma (Kojic Acid combination), Skin Lightening Agent (Glutathione + Aloe Vera), Moisturizer.